Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Brain scans and imaging

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Varying degrees of cortical amyloid deposition are reported in the setting of Parkinsonism with cognitive impairment. We performed a systematic review to estimate the prevalence of Alzheimer disease (AD) range cortical amyloid deposition among patients with Parkinson's disease with dementia (PDD), Parkinson's disease with mild cognitive impairment (PD-MCI) and dementia with Lewy bodies (DLB). We included amyloid positron emission tomography (PET) imaging studies using Pittsburgh Compound B (PiB). Methods We searched the databases Ovid MEDLINE, PubMed, Embase, Scopus, and Web of Science for articles pertaining to amyloid imaging in Parkinsonism and impaired cognition. We identified 11 articles using PiB imaging to quantify cortical amyloid. We used the metan module in Stata, version 11.0, to calculate point prevalence estimates of patients with "PiB-positive" studies, that is, patients showing AD range cortical Aβ-amyloid deposition. Heterogeneity was assessed. A scatterplot was used to assess publication bias. Results Overall pooled prevalence of "PiB-positive" studies across all three entities along the spectrum of Parkinson's disease and impaired cognition (specifically PDD, PD-MCI, and DLB) was 0.41 (95% confidence interval [CI], 0.24-0.57). Prevalence of "PiB-positive" studies was 0.68 (95% CI, 0.55-0.82) in the DLB group, 0.34 (95% CI, 0.13-0.56) in the PDD group, and 0.05 (95% CI, -0.07-0.17) in the PD-MCI group. Conclusions Substantial variability occurs in the prevalence of "PiB-positive" studies in subjects with Parkinsonism and cognitive impairment. Higher prevalence of PiB-positive studies was encountered among subjects with DLB as opposed to subjects with PDD. The PD-MCI subjects showed overall lower prevalence of PiB-positive studies than reported findings in non-PD-related MCI. © 2015 International Parkinson and Movement Disorder Society.

What this study adds

Evidence grade: High

This is a pooled review. This systematic review of amyloid PET studies found that about 41% of people across Parkinson's disease with dementia, Parkinson's disease with mild cognitive impairment, and dementia with Lewy bodies were amyloid-positive. It describes how often amyloid is present in these related conditions and does not test treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Petrou, M., Dwamena, B. A., Foerster, B. R., MacEachern, M. P., Bohnen, N. I., Müller, M. L., et al. (2015). Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Movement disorders : official journal of the Movement Disorder Society. https://doi.org/10.1002/mds.26191

Vancouver

Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Müller ML, et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Movement disorders : official journal of the Movement Disorder Society. 2015. doi:10.1002/mds.26191. PMID: 25879534.

BibTeX

@article{petrou2015-25879534,
  author  = {Petrou, M. and Dwamena, B. A. and Foerster, B. R. and MacEachern, M. P. and Bohnen, N. I. and Müller, M. L. and Albin, R. L. and Frey, K. A.},
  title   = {{Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review}},
  journal = {Movement disorders : official journal of the Movement Disorder Society},
  year    = {2015},
  doi     = {10.1002/mds.26191},
  pmid    = {25879534},
  url     = {https://doi.org/10.1002/mds.26191}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

This systematic review of amyloid PET studies found that about 41% of people across Parkinson's disease with dementia, Parkinson's disease with mild cognitive impairment, and dementia with Lewy bodies were amyloid-positive. It describes how often amyloid is present in these related conditions and does not test treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 64/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 64 of 100.64 of 100 points earned36 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Movement disorders : official journal of the Movement Disorder Society)
Journal's citation record 3 / 4 Movement Disorders: journal h-index 281 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2015 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 5 / 7 Cited 222 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 17.1 citations a year over 13 year(s) since 2015
Impact for its field and year 3 / 6 Cited 3.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 16 other studies in this library
Still being cited 3 / 4 Cited 55 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Kirk A. Frey: h-index 82 (OpenAlex, whole career)
Institution's track record 2 / 3 Johns Hopkins University: institution h-index 2,306 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 25879534)
Free to read 0 / 2 Behind a paywall — scores zero
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.

Later studies that cite this one

16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Brain scans and imaging from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Brain scans and imaging

See all studies in Brain scans and imaging →